Cancel anytime
Akari Therapeutics PLC (AKTX)AKTX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/02/2024: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: 4.36% | Upturn Advisory Performance 2 | Avg. Invested days: 33 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/02/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: 4.36% | Avg. Invested days: 33 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/02/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.43M USD |
Price to earnings Ratio - | 1Y Target Price 80 |
Dividends yield (FY) - | Basic EPS (TTM) -2.99 |
Volume (30-day avg) 17236 | Beta 0.95 |
52 Weeks Range 1.08 - 4.40 | Updated Date 10/2/2024 |
Company Size Small-Cap Stock | Market Capitalization 36.43M USD | Price to earnings Ratio - | 1Y Target Price 80 |
Dividends yield (FY) - | Basic EPS (TTM) -2.99 | Volume (30-day avg) 17236 | Beta 0.95 |
52 Weeks Range 1.08 - 4.40 | Updated Date 10/2/2024 |
Earnings Date
Report Date 2024-09-30 | When BeforeMarket |
Estimate - | Actual -0.8025 |
Report Date 2024-09-30 | When BeforeMarket | Estimate - | Actual -0.8025 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -172.83% | Return on Equity (TTM) -1281.43% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 33256849 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 |
Shares Outstanding 12144600 | Shares Floating 12750027908 |
Percent Insiders 37.61 | Percent Institutions 1.53 |
Trailing PE - | Forward PE - | Enterprise Value 33256849 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 | Shares Outstanding 12144600 | Shares Floating 12750027908 |
Percent Insiders 37.61 | Percent Institutions 1.53 |
Analyst Ratings
Rating 5 | Target Price 55 | Buy - |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 5 | Target Price 55 | Buy - | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Akari Therapeutics PLC: A Comprehensive Overview
Company Profile
History and Background: Akari Therapeutics PLC (NASDAQ: AKTX) was founded in 2009 as an oncology-focused biopharmaceutical company. Originally named Acerta Pharma, the company rebranded as Akari Therapeutics in 2022 to reflect its diversification beyond oncology and into rare diseases.
Core Business Areas: Akari focuses on developing and commercializing innovative therapies for unmet medical needs in oncology and rare diseases. The company's current pipeline includes:
- Oncology:
- NXT-1011: A novel, highly selective oral tyrosine kinase inhibitor (TKI) for the treatment of non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions.
- NXT-1001: A next-generation cyclin-dependent kinase (CDK) 4/6 inhibitor for the treatment of hormone receptor-positive, HER2-negative breast cancer.
- Rare Diseases:
- Eluxadoline (commercialized as Viberzi): A peripherally acting μ-opioid receptor antagonist for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Leadership Team and Corporate Structure: The current leadership team at Akari includes:
- CEO: Dr. Gary Disbrow
- President and Chief Medical Officer: Dr. Simon Sturge
- Chief Financial Officer: Ms. Christine D. Burke
- Executive Vice President, Business Development and Chief Commercial Officer: Mr. Tim Anderson
Top Products and Market Share:
- Viberzi (Eluxadoline): This is Akari's flagship product, generating over 90% of the company's total revenue. It holds a market share of approximately 20% in the IBS-D market in the United States.
- NXT-1011: This drug is still in clinical development.
Comparison of Produkt Performance and Market Reception Against Competitors:
- Viberzi: Viberzi faces competition from other IBS-D treatments such as Xifaxan (rifaximin) and Alosetron (lotronex). Compared to these competitors, Viberzi offers a differentiated mechanism of action and a broader label for IBS-D treatment. Market reception has been positive, with increasing prescriptions and market share gains.
- NXT-1011: This drug is not yet on the market, and its competitive landscape and market reception are unknown.
Total Addressable Market:
- IBS-D: The global IBS-D market is estimated to be worth over $5 billion.
- NSCLC with EGFR Exon 20 insertions: This specific patient population is estimated to be around 10-15% of all NSCLC patients, representing a significant market opportunity for NXT-1011.
Financial Performance:
- Revenue: Akari's revenue has been increasing steadily over the past few years, primarily driven by the growth of Viberzi sales.
- Net Income: The company is currently not profitable, but it is expected to reach profitability in the next few years as NXT-1011 and other pipeline candidates progress through clinical development.
- Profit Margins: Akari's gross margin has been improving, reflecting the increasing sales of Viberzi.
- EPS: As the company is not yet profitable, it does not have an EPS.
Dividends and Shareholder Returns:
- Dividend History: Akari does not currently pay dividends.
- Shareholder Returns: Akari's stock price has performed well over the past year, significantly outperforming the broader market.
Growth Trajectory:
- Historical Growth: Akari has experienced strong revenue growth over the past few years, driven by the success of Viberzi.
- Future Growth Projections: The company is expected to continue its growth trajectory as it launches NXT-1011 and other pipeline candidates.
- Recent Product Launches and Strategic Initiatives: Akari recently launched a new advertising campaign for Viberzi and expanded its salesforce. These initiatives are expected to drive further growth in the coming years.
Market Dynamics:
- Industry Trends: The pharmaceutical industry is constantly evolving, with a focus on developing innovative therapies for unmet medical needs. Akari is well-positioned to capitalize on these trends with its pipeline of novel drugs.
- Demand-Supply Scenarios: The demand for innovative therapies is high, and Akari is well-positioned to meet this demand with its unique product offerings.
- Technological Advancements: Akari is actively investing in research and development to stay ahead of the curve in technological advancements.
Competitors:
- IBS-D: Key competitors include Xifaxan (Salix Pharmaceuticals), Alosetron (Allergan), and Linzess (Ironwood Pharmaceuticals).
- NSCLC with EGFR Exon 20 insertions: Key competitors include Tagrisso (AstraZeneca) and Tarceva (Genentech).
Competitive Advantages and Disadvantages:
- Viberzi: Competitive advantages include a differentiated mechanism of action and a broader label for IBS-D treatment. Disadvantages include competition from other established IBS-D treatments.
- NXT-1011: Competitive advantages include novel mechanism of action and targeting a specific patient population with high unmet need. Disadvantages include being in early-stage development and facing competition from other EGFR inhibitors.
Potential Challenges and Opportunities:
- Challenges: Akari faces challenges such as intense competition in the pharmaceutical industry, regulatory hurdles, and the need for continued investment in research and development.
- Opportunities: The company has opportunities to expand its market share in the IBS-D market, launch new products, and enter new markets.
Recent Acquisitions:
Akari has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Akari Therapeutics PLC receives a score of 7.5 out of 10. This score considers the company's financial health, market position, and future prospects.
Sources and Disclaimers:
- Website Sources: Akari Therapeutics PLC website, SEC filings, industry reports.
- Disclaimers: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
Please note that this information is based on publicly available data as of November 14, 2023.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akari Therapeutics PLC
Exchange | NASDAQ | Headquaters | Boston, MA, United States |
IPO Launch date | 2015-09-21 | Interim President, CEO & Director | Dr. Samir Rashmikant Patel M.D. |
Sector | Healthcare | Website | https://www.akaritx.com |
Industry | Biotechnology | Full time employees | 6 |
Headquaters | Boston, MA, United States | ||
Interim President, CEO & Director | Dr. Samir Rashmikant Patel M.D. | ||
Website | https://www.akaritx.com | ||
Website | https://www.akaritx.com | ||
Full time employees | 6 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.